University of Maryland School of Medicine (UMSOM) Names William F. Regine, MD, Senior Associate Dean for Clinical Affairs
· Filed In: Healthcare News
William F. Regine, MD, has been appointed to the executive role of senior associate dean for clinical affairs at the University of Maryland School of Medicine (UMSOM).
An internationally renowned physician-scientist known for his work in the use of stereotactic radiosurgery, as well as for his research efforts with gastrointestinal and central nervous system malignancies, Regine currently is the Isadore & Fannie Schneider Foxman Chair of Radiation Oncology and executive director of the Maryland Proton Treatment Center (MPTC).
In his new role, Regine will serve as UMSOM’s chief physician, overseeing clinical care, business, and other matters related to the school’s clinical faculty. In conjunction with UMSOM Dean Mark Gladwin, MD, he will lead school-wide clinical initiatives, while developing business and delivery strategies for the clinical mission involving in-patient and out-patient practices.
He also will meet regularly with senior leadership at the University of Maryland Medical Center (UMMC) and the University of Maryland Medical System (UMMS) to solve problems, review opportunities, and strengthen relationships, while serving as a senior liaison between UMSOM and the Veterans Administration Medical Center on clinical initiatives.
Concurrently, in his appointment as the new President of University of Maryland Faculty Physicians, Inc. (FPI), Regine will lead strategic efforts in financial growth and success for this organization, made up of more than 1,200 UMSOM faculty members, who provide care to more than 1.5 million outpatients and inpatients every year. FPI treats patients at more than 60 offices located across Maryland, as well as delivering all clinical care at UMMC and several other UMMS hospitals.
Regine will retain his position as executive director of the MPTC, where he leads the first and most advanced facility of its kind in the Baltimore-Washington region, providing nearly 2,000 cancer patients a year with precise, “pencil-beam” technology to treat solid tumors. He also will remain chair of the department of radiation oncology, a post he has held since 2003. The department, which has pioneered radiation treatment in cancer, has achieved a Top 5 national ranking in National Institutes of Health research funding.
About University of Maryland School of Medicine:
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.
The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world.
The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows.
While our medical students comprise nearly half of the total student enrollment, our student body also includes Allied Health and Physical Therapy students, as well as graduate students and students pursuing combined degrees. We currently have ten joint degree programs: two doctorate programs (MD/PhD and MD/DDS), seven MD/Master’s degree programs, and a DPT/PhD degree program within the Department of Physical Therapy & Rehabilitation Sciences.
About William F. Regine, MD:
Dr. Regine leads a department which has achieved a Top 5 national ranking in National Institutes of Health research funding. He is recognized nationally and internationally in the areas of gastrointestinal and central nervous system malignancies and in the use of stereotactic radiosurgery (SRS). As Executive Director of the Maryland Proton Treatment Center, he leads the first and most advanced facility of its kind in the Baltimore-Washington, DC region -- providing nearly 2,000 cancer patients a year with precise, "pencil-beam" technology to treat solid tumors.
Dr. Regine has served as principal or co-principal Investigator in at least four National Cancer Institute (NCI)-sponsored cooperative group clinical trials. He has been a member of the GI and Brain Tumor steering committees for the NCI sponsored national cooperative clinical trials group known as NRG Oncology, and has been the chairman of the GI section of the National Oral Board examination for trainees in radiation oncology. Dr. Regine served as the principal investigator of a study evaluating adjuvant therapy in patients with pancreatic cancer, which defined a new standard of care. He also has been the principal investigator/study chairman for two institutional clinical trials that defined new standards of care for patients with brain metastases and malignant spinal cord compression. Dr. Regine is co-editor of Principles and Practices of Stereotactic Radiosurgery, the first comprehensive textbook of its kind. He is also co-inventor of the first of its kind treatment device completely dedicated to the stereotactic radiation treatment of early stage breast cancer, known as the GammaPod.